

Appendix 8 (as supplied by the authors): Subgroup analysis of Risk of Cardiovascular Death Among Patients Using ARBs and ACEIs

Characteristic	Hazard Ratio* (95% CI)	P Value	Interaction P Value
Gender			
Male	1.009 (0.845-1.205)	0.9	0.9
Female	0.989 (0.798-1.225)	0.9	
Age			
20-64 years	1.135 (0.946-1.361)	0.2	0.04
≥ 65 years	0.854 (0.694-1.051)	0.1	
Charlson Comorbidity Index score			
2	1.229 (0.923-1.635)	0.2	0.1
3	0.769 (0.558-1.060)	0.1	
4	0.869 (0.619-1.220)	0.4	
≥ 5	1.081 (0.877-1.334)	0.5	
Hypertension			
Yes	0.988 (0.858-1.138)	0.9	0.3
No	1.315 (0.771-2.241)	0.3	
Chronic kidney disease			
Yes	1.083 (0.841-1.396)	0.5	0.5
No	0.979 (0.833-1.152)	0.8	
Heart failure			
Yes	1.045 (0.774-1.411)	0.8	0.8
No	0.995 (0.853-1.160)	0.9	
Coronary artery disease			
Yes	1.052 (0.838-1.321)	0.7	0.6
No	0.982 (0.828-1.165)	0.8	

* Adjusted for propensity score; ACEI cohort: reference group

Abbreviations: CI, confidence interval; ARBs, Angiotensin II receptor blockers; ACEIs, angiotensin-converting-enzyme inhibitors; RAAS, Renin-angiotensin-aldosterone system.